TORONTO, ON, JANUARY 13, 2020 –– INTELLiSTEM Technologies, an international biotechnology company revolutionizing cell therapy, announces today the launch of IntelliPeptidomeTM, a novel Drug Discovery Platform for rapid and systematic identification of MHC/HLA bound peptide candidates for various clinical applications. [Read more…]
CAR-T Cell Therapy Attracts Vast Sums of Money
What is CAR-T therapy? Chimeric antigen receptor T-cell (CAR-T) therapy is a targeted approach to treating cancer that uses a patient’s T cells, which are a type of immune system cell.
Since the first CAR-T therapy approvals in 2017 by the U.S. FDA, CAR-T deal-making has attracted vast sums of money. This article summarizes recent partnerships and deal-making with the CAR-T marketplace. [Read more…]
Cellectis Secures 82,000 Sq Ft Manufacturing Facility in Raleigh to Compliment Paris Facility
Cellectis, a leading French biopharmaceutic company, has signed a lease agreement for an 82,000 sq. ft. manufacturing facility in Raleigh, North Carolina, to complement its existing 14,000 sq. ft. manufacturing facility in Paris, France.
Located at 2500 – 2540 Sumner Boulevard in Raleigh, NC, the new USA facility is owned by Equus Capital Partners and will be used for clinical and commercial production of Cellectis’ leading allogeneic UCART products.
Importantly, the decision will combine the capabilities of Cellectis’ two facilities to advance its manufacturing processes and prepare for potential commercialization of its UCART products in the future. [Read more…]
Gilead Gets Notice of Compliance for Yescarta™ from Health Canada
Yescarta™ is positioned to join Kymriah™ as the second chimeric antigen receptor T cell (CAR-T) therapy to achieve regulatory approval in Canada, based on exciting news released this month from Gilead Sciences Canada. [Read more…]
Australian TGA Approves Novartis’ Kymriah® CAR-T Therapy for Two Blood Cancers
Kymriah® (tisagenlecleucel), CAR-T therapy from Novartis, receives TGA approval for treating two aggressive blood cancers
- Kymriah® is an immunocellular therapy that is a one-time treatment manufactured individually for each patient using the patient’s own T cells, genetically reengineered and programmed to recognise and destroy cancer cells.
- Kymriah® is approved for the treatment of relapsed or refractory patients with paediatric B-cell acute lymphoblastic leukaemia (ALL) and adult diffuse large B-cell lymphoma (DLBCL)[1]
- Kymriah® could be a treatment option for about 50 paediatric and young adult ALL patients and 420 adult DLBCL patients who relapse or do not respond to initial therapy[2]
- Kymriah® is the only chimeric antigen receptor T cell (CAR-T) therapy to receive TGA approval in Australia[1]